Filters
Psychedelics
Hedge Fund Billionaire Steve Cohen is Betting on Psychedelics
Steve Cohen’s hedge fund Point 72, which boasts over $26 billion in assets, disclosed in a new filing they have purchased over 18M shares of Cybin (NYSE:CYBN)
September 16, 2023
Biotech
Psychedelics
Public Companies
Psychedelics
MDMA For PTSD Moves Closer to Groundbreaking FDA Approval
The long awaited results from the MAPS Phase III clinical trial on MDMA as a therapeutic for PTSD have finally been announced.
September 14, 2023
Psychedelics
Biotech
Psychedelics
The Next Era For Psychedelic Companies
While it’s still early, it is becoming clear that psychedelic medicine companies are entering into a new M&A era with traditional biotech majors.
September 1, 2023
Psychedelics
Public Companies
Psychedelics
Psychedelic Biotech Lands $125 Million For Psilocybin Clinical Trials
COMPASS Pathways Secures $125M for Breakthrough Psychedelic Therapy: Advancing COMP360's Phase III FDA Trial. Major Investors Back Pioneering Treatment.
August 18, 2023
Psychedelics
Discover the world's most disruptive early stage companies with 25,000+ investors.
The markets and trends that matter, made simple.
Join top talent at the world's most respected institutions, companies, and venture capital funds.